论文部分内容阅读
目的 :研究利巴韦林喷雾剂联合蒲地蓝消炎口服液治疗手足口病58例的临床效果。方法 :选择我单位门诊治疗的58例手足口病患者(治疗时间2013.01~2017.01),使用随机分组方式分为2组/29例,对照组接受利巴韦林喷雾剂治疗,实验组接受利巴韦林喷雾剂联合蒲地蓝消炎口服液治疗,观察2组患者的总病程、体温恢复正常时间、皮疹消退时间、口腔溃疡好转时间及不良反应发生情况。结果:实验组患者总病程、体温恢复正常时间、皮疹消退时间、口腔溃疡好转时间及不良反应发生率较对照组均更具优势(P<0.05)。结论 :利巴韦林喷雾剂联合蒲地蓝消炎口服液治疗手足口病患者安全有效,对于临床推广具有积极作用。
Objective: To study the clinical efficacy of ribavirin spray combined with Pudicam anti-inflammatory oral liquid in the treatment of 58 cases of hand-foot-mouth disease. Methods: Fifty-eight patients with hand-foot-mouth disease (outpatient period from January 2013 to January 2017) were selected and randomly divided into two groups (n = 29). The control group received ribavirin (n = Weilin spray combined PuDiLan anti-inflammatory oral liquid treatment to observe the two groups of patients with the total duration of normal body temperature recovery, rash subsided time, mouth ulcers improved time and adverse reactions occurred. Results: The total duration of disease, the normal time of body temperature recovery, the time of rash subsidence, the time of improvement of oral ulcer and the incidence of adverse reactions in the experimental group were all superior to those in the control group (P <0.05). Conclusion: The combination of ribavirin spray and Pudilan anti-inflammatory oral liquid for the treatment of HFMD patients is safe and effective, which has a positive effect on clinical promotion.